Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 19/20 | 0.57 |
| ▸ | CTSK | P43235 | 16/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12712549 | 0.88 | CTSS (0.74) | CTSSCTSKCTSLCTSB | |
| SCHEMBL18884395 | 0.88 | CTSS (0.74) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24814157 | 0.86 | CTSS (0.48) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29178361 | 0.86 | CTSS (0.48) | CTSSCTSKCTSLCTSB | |
| SCHEMBL939477 | 0.86 | CTSS (0.50) | CTSSCTSKCTSLCTSB | |
| SCHEMBL305190 | 0.86 | CTSS (0.50) | CTSSCTSKCTSLCTSB | |
| SCHEMBL755894 | 0.86 | CTSS (0.50) | CTSSCTSKCTSLCTSB | |
| SCHEMBL15582702 | 0.83 | CTSS (0.48) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24344775 | 0.83 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL12973256 | 0.83 | CTSK (0.47) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-2949665-B1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-2949665-B1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2949665-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-02 | — | — | EP | disclosed |
| EP-2949665-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014115797-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | 第一三共株式会社 (JP) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | NPPA, NPR1, NPR3 | CTSS 3994/4885CTSK 3394/4885CTSL 2139/4885 |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | CTSS 3994/4885CTSK 3394/4885CTSL 2139/4885 |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | CTSS 3994/4885CTSK 3394/4885CTSL 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.